Share

WuXi Biologics (2269.HKEX) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 5 June 2026Deep analysis 5 June 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

12 AI Advisor Reports

Select an advisor report.

Sherlock Holmes AI

The Whistleblower FrameworkAI Researcher

Model rating

Strong Buy

5-Year Return Est.

+204.8%

2269.HKEX does not currently pay dividends

1. Investment Thesis — Base Case

WuXi Biologics is the ultimate 'Dog That Didn't Bark' case study in financial markets. The consensus prepared for a regulatory execution that never materialized. The final 2025 BIOSECURE Act conspicuously omitted explicit designation of WuXi Biologics, offering a critical reprieve and a five-year safe harbor that the market continues to misprice. More importantly, the financial forensics reveal a business structurally insulated by extreme switching costs. Despite peak geopolitical tension, US and European clients accounted for two-thirds of the 69 new projects signed by April 2026. This hard evidence proves the Alpha Gap: Western biopharma relies absolutely on WuXi's advanced capabilities in complex modalities (ADCs and bispecifics), which cannot be rapidly re-shored. The base case sees the geopolitical discount gradually collapse as continuous, robust free cash flow generation and strategic ex-China capacity expansions (Singapore, USA) dilute the perceived sovereign risk.

The 16x trailing P/E is absurdly cheap for a structural 15-20% grower with a monopolistic moat.
Gross margins of 46% validate absolute pricing power in complex modalities, not commoditized manufacturing.
The five-year safe harbor provides ample runway to optimize global capacity without client disruption.
Strong cash conversion (+70% YoY) fully self-funds expansion CapEx, entirely avoiding dilution.
While DoD 1260H risk remains, the fundamental compounding momentum vastly outweighs the probabilistic geopolitical tail risk, given global money supply constraints.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in HKD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (HKD)
Observed price	2021-05-31	121
Observed price	2021-06-08	120
Observed price	2021-06-24	141
Observed price	2021-06-28	144
Observed price	2021-07-06	126
Observed price	2021-08-07	128
Observed price	2021-08-19	114
Observed price	2021-08-23	113
Observed price	2021-09-08	122
Observed price	2021-09-28	124
Observed price	2021-10-10	110
Observed price	2021-10-26	120
Observed price	2021-11-07	102
Observed price	2021-11-19	111
Observed price	2021-12-05	100
Observed price	2021-12-13	98.2
Observed price	2022-01-06	80.0
Observed price	2022-01-14	91.0
Observed price	2022-01-30	76.0
Observed price	2022-02-07	80.6
Observed price	2022-02-11	56.7
Observed price	2022-03-15	41.0
Observed price	2022-03-27	65.7
Observed price	2022-04-04	69.5
Observed price	2022-04-24	54.2
Observed price	2022-05-02	58.4
Observed price	2022-05-06	50.4
Observed price	2022-05-30	57.1
Observed price	2022-06-23	70.0
Observed price	2022-07-01	74.6
Observed price	2022-07-21	80.7
Observed price	2022-07-25	81.3
Observed price	2022-08-18	69.0
Observed price	2022-08-30	70.3
Observed price	2022-09-15	54.1
Observed price	2022-09-23	46.4
Observed price	2022-10-05	49.3
Observed price	2022-10-17	50.6
Observed price	2022-10-29	38.6
Observed price	2022-11-26	48.0
Observed price	2022-12-04	53.9
Observed price	2022-12-16	49.0
Observed price	2023-01-05	67.5
Observed price	2023-01-13	72.6
Observed price	2023-02-02	66.5
Observed price	2023-02-10	65.4
Observed price	2023-02-26	53.8
Observed price	2023-03-06	56.2
Observed price	2023-03-18	48.3
Observed price	2023-04-03	47.0
Observed price	2023-04-15	54.0
Observed price	2023-05-05	47.0
Observed price	2023-05-25	43.9
Observed price	2023-06-02	44.5
Observed price	2023-06-22	38.1
Observed price	2023-06-30	36.5
Observed price	2023-07-16	40.8
Observed price	2023-07-24	40.5
Observed price	2023-08-05	44.6
Observed price	2023-08-21	39.8
Observed price	2023-08-29	46.0
Observed price	2023-09-22	42.6
Observed price	2023-10-12	48.0
Observed price	2023-10-20	46.0
Observed price	2023-11-09	50.4
Observed price	2023-11-13	48.8
Observed price	2023-12-07	29.9
Observed price	2023-12-15	29.5
Observed price	2023-12-27	27.5
Observed price	2024-01-12	30.2
Observed price	2024-02-01	18.64
Observed price	2024-02-13	16.05
Observed price	2024-02-25	18.68
Observed price	2024-03-04	19.66
Observed price	2024-03-28	13.83
Observed price	2024-04-09	14.40
Observed price	2024-04-25	12.74
Observed price	2024-05-03	14.63
Observed price	2024-05-23	12.88
Observed price	2024-05-31	11.14
Observed price	2024-06-16	12.00
Observed price	2024-06-24	11.81
Observed price	2024-07-10	10.66
Observed price	2024-07-30	10.50
Observed price	2024-08-11	11.54
Observed price	2024-08-19	11.92
Observed price	2024-08-23	10.26
Observed price	2024-09-16	11.52
Observed price	2024-10-06	21.8
Observed price	2024-10-30	16.36
Observed price	2024-11-07	17.54
Observed price	2024-11-11	16.82
Observed price	2024-11-23	14.71
Observed price	2024-12-09	19.00
Observed price	2024-12-17	16.84
Observed price	2025-01-06	16.38
Observed price	2025-01-30	18.47
Observed price	2025-02-03	18.48
Observed price	2025-02-23	24.7
Observed price	2025-03-03	22.4
Observed price	2025-03-19	28.5
Observed price	2025-03-31	27.1
Observed price	2025-04-08	18.39
Observed price	2025-05-06	22.2
Observed price	2025-05-22	24.3
Observed price	2025-05-26	23.7
Observed price	2025-06-11	27.1
Observed price	2025-06-23	25.1
Observed price	2025-07-17	28.3
Observed price	2025-07-21	28.0
Observed price	2025-07-29	33.6
Observed price	2025-08-18	31.0
Observed price	2025-09-07	37.3
Observed price	2025-09-19	37.8
Observed price	2025-10-05	42.0
Observed price	2025-10-29	36.8
Observed price	2025-11-06	34.4
Observed price	2025-11-14	33.9
Observed price	2025-11-22	30.9
Observed price	2025-12-20	33.8
Observed price	2026-01-01	31.9
Observed price	2026-01-05	33.5
Observed price	2026-01-13	39.8
Observed price	2026-02-02	35.9
Observed price	2026-02-22	41.5
Observed price	2026-03-02	37.8
Observed price	2026-03-26	32.8
Observed price	2026-03-30	32.9
Observed price	2026-04-15	37.0
Observed price	2026-05-01	34.2
Observed price	2026-05-17	32.9
Observed price	2026-06-02	35.1
Observed price	2026-06-10	29.7
Observed price	2026-06-22	31.1
Observed price	2026-07-16	39.3
Observed price	2026-07-20	38.3
Observed price	2026-08-09	46.0
Observed price	2026-08-17	46.2
Observed price	2026-08-25	52.2
Observed price	2026-09-14	49.1
Observed price	2026-09-18	50.4
Published advisor forecast	2026-06-04	32.4
Published advisor forecast	2026-09-04	38.3
Published advisor forecast	2026-12-04	42.8
Published advisor forecast	2027-03-04	47.1
Published advisor forecast	2027-06-04	45.2
Published advisor forecast	2027-09-04	48.9
Published advisor forecast	2027-12-04	56.2
Published advisor forecast	2028-03-04	60.7
Published advisor forecast	2028-06-04	57.7
Published advisor forecast	2028-09-04	61.1
Published advisor forecast	2028-12-04	66.6
Published advisor forecast	2029-03-04	69.9
Published advisor forecast	2029-06-04	67.8
Published advisor forecast	2029-09-04	72.6
Published advisor forecast	2029-12-04	77.0
Published advisor forecast	2030-03-04	83.1
Published advisor forecast	2030-06-04	79.8
Published advisor forecast	2030-09-04	83.8
Published advisor forecast	2030-12-04	89.6
Published advisor forecast	2031-03-04	93.2
Published advisor forecast	2031-06-04	98.8

2. Scenarios & Signals

Bull case

The geopolitical overhang fully dissipates, validating the bull case. The US Department of Defense officially clears WuXi Biologics from the 1260H list, acknowledging its lack of military affiliation and permanently removing the uninvestable stigma. Simultaneously, the wave of 74 Phase III programs transitions into commercial manufacturing, unlocking exponential revenue scale with minimal marginal cost. explodes, driving aggressive share buybacks and a multiple re-rating toward 30x P/E.

DoD 1260H clearance removes institutional constraints and passive-flow blockades.
Commercial manufacturing scale triggers massive operating leverage, pushing net margins past 25%.
The 'Follow and Win the Molecule' strategy achieves a near-100% retention rate in late-stage trials.

Bear case

The US government weaponizes the 1260H list, officially designating WuXi Biologics as a 'Biotechnology Company of Concern.' Even with a safe harbor, new US contract flow immediately freezes, and the terminal value collapses. Concurrently, the Warsh-led hawkish rate regime chokes off venture capital funding to early-stage biotech, causing WuXi's pre-IND project funnel to completely dry up.

US and European biopharma initiate immediate supply chain diversification, destroying the Western revenue base over 5 years.
Heavy deployed in Singapore and Ireland becomes stranded assets with insufficient utilization.
Severe margin compression ensues due to desperate price wars with Samsung Biologics and Lonza to retain remaining Asian volume.

Current crowd narrative

The crowd is entirely anchored to the geopolitical fear that US-China decoupling via the will systematically dismantle WuXi Biologics' Western revenue base. Media narratives obsess over 'China risk' and treat the stock as uninvestable, preemptively grouping it with formally sanctioned entities. The consensus treats every geopolitical headline as an existential threat, completely disregarding the company's record financial performance, its massive , and treating its distressed 16x P/E multiple as a permanent 'value trap' reflective of guaranteed terminal risk.

Alpha-gap assessment

The variant perception lies in the stark contradiction between political rhetoric and pharmaceutical reality. While the consensus market prices WuXi Biologics as a toxic asset destined to lose its US clientele due to the , the forensic evidence—specifically the addition of 69 new integrated projects by April 2026, predominantly from the US and EU—proves that Western biopharma cannot easily substitute WuXi's dominance in complex and bispecifics. The final legislation's omission of WuXi's name and the explicit five-year safe harbor provide a massive operational runway. The is the market systematically mispricing high and specialized CDMO moats for generic geopolitical noise.

Convergence catalyst

The convergence will occur as successive quarterly earnings reports in late 2026 and 2027 continuously demonstrate US revenue resilience and commercial pipeline conversion. This undeniable cash-flow reality will force institutional capital to re-underwrite the stock based on its 20% earnings CAGR rather than geopolitical headlines, triggering a violent short squeeze.

Macro-regime alignment

The 'Warsh-era' higher-for-longer rate regime acts as a headwind for venture-backed early-stage biotech funding, slightly threatening WuXi's pre-IND funnel. However, the overarching macro environment heavily penalizes unprofitable speculation and deeply rewards unencumbered free cash flow, pristine balance sheets, and structural margin expansion; traits where WuXi Biologics overwhelmingly excels, providing immense downside support.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.7
Expected volatility regime: high_erratic
Convergence-cycle position: early_discovery

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
US Biopharma Contract Acceleration	Despite the oppressive BIOSECURE narrative, the forensic evidence reveals that US and European customers accounted for roughly two-thirds of the 69 new project wins by April 2026. The mechanism driving this upward price pressure is the extreme switching cost inherent in biologics contract manufacturing. Western biopharma simply cannot replace WuXi's specialized expertise and massive capacity in complex modalities like ADCs and bispecifics overnight. As long as the company continues to execute flawlessly, clients will exploit the five-year safe harbor to retain the best-in-class provider. This relentless accumulation of new Western contracts completely invalidates the bearish thesis of an immediate revenue collapse. As these early-stage wins mature into high-value commercial manufacturing contracts over the next five years, they will drive sustained revenue compounding that will mathematically force the stock price higher.	Not available%	+45.0%
Biosecure ACT SAFE Harbor Runway	The final December 2025 NDAA/BIOSECURE Act consciously omitted explicitly naming WuXi Biologics as a target, contrary to earlier terrifying drafts. Furthermore, it established a five-year safe harbor for existing contracts. The mechanism of this tailwind is the removal of the immediate regulatory execution risk. It transforms a perceived sudden-death scenario into a highly manageable, multi-year transition period. This runway allows Western biopharma to legally maintain and expand their current pipelines with WuXi without violating federal mandates. The market initially priced the stock for imminent zeroing in the US; the reality of the explicit safe harbor means cash flows remain protected through the end of the decade, providing ample time for the geopolitical discount to compress as continuous earnings invalidate the panic.	Not available%	+40.0%
Complex Modality Margin Expansion	The explosive growth in advanced therapeutics, specifically antibody-drug conjugates (ADCs) and bispecifics, is driving structural gross margin expansion. These complex modalities grew over 120% YoY in 2025 and drove gross margins up 500 basis points to 46%. The mechanism here is pricing power; WuXi is not competing on commoditized stainless-steel tank volume, but on highly specialized scientific execution that commands premium pricing. This mix-shift toward high-value modalities acts as a massive tailwind for net income growth. As the industry pivots further toward targeted oncology and complex biologics over the five-year horizon, WuXi's entrenched technological lead will persistently expand operating margins, driving earnings surprises and triggering sequential valuation re-ratings as the market recognizes the insurmountable intellectual property moat.	Not available%	+35.0%
Strategic Asset Divestiture & RING Fenci	The strategic $521M sale of the Irish vaccine facility to Merck demonstrates proactive capital reallocation to de-risk geographically while harvesting cash. The mechanism is a deliberate 'friend-shoring' optimization: management is successfully liquidating non-core assets at premium valuations to fund the aggressive expansion of the 'Global Dual Sourcing' network across Singapore and the United States. This decisively mitigates the geopolitical risk profile. By building autonomous, fully compliant manufacturing hubs outside of China, WuXi Biologics strips the 'China-risk' discount from its Western revenue streams. This geographic ring-fencing ensures that even under maximum US-China regulatory stress, the company can seamlessly service its US and European clientele from compliant jurisdictions, guaranteeing the preservation of its massive 23.7B USD backlog.	Not available%	+25.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Ongoing 1260h LIST Threat	While WuXi Biologics was conspicuously omitted from the explicit text of the final 2025 BIOSECURE Act, the Department of Defense's 1260H list remains a potent sword of Damocles. If the US DoD or OMB formally designates them as a 'Biotechnology Company of Concern' in the future, federal funding restrictions will apply. This persistent geopolitical overhang artificially compresses the valuation multiple, as risk-averse institutional compliance departments preemptively restrict accumulation. The mechanism of this drag is purely narrative and regulatory, divorced from the pristine financial fundamentals. However, as long as US-China decoupling remains a bipartisan political necessity in Washington, the threat of sudden sanctions will enforce a structural risk premium on the stock, capping aggressive multiple expansion even as the underlying earnings continue to compound flawlessly over the horizon.	Not available%	-35.0%
Warsh ERA Biotech Funding Squeeze	The higher-for-longer interest rate regime, solidified under the Warsh-led Federal Reserve, acts as a structural headwind for pre-revenue biotechnology firms. The mechanism of this friction is the increased cost of capital; as venture capital and public equity markets tighten funding for early-stage biotech, the top of WuXi Biologics' 'Pre-IND' project funnel is inevitably constrained. While WuXi's late-stage commercial manufacturing provides immense cash flow, the long-term growth engine relies on capturing molecules early in their lifecycle. A sustained drought in biotech funding will ultimately slow the volume of new early-phase contracts entering the pipeline. This macrofinancial drag acts as a slow-burning friction, marginally reducing the long-term organic growth rate of the research and discovery segments.	Not available%	-15.0%
Geopolitical Capex Duplication	The political necessity of expanding the 'Global Dual Sourcing' network, particularly the aggressive build-out of facilities in Singapore and the United States, introduces a structural drag on return on invested capital (ROIC). The mechanism is redundant capacity capitalization. Instead of centralizing manufacturing in low-cost, high-efficiency Chinese mega-facilities, the company is forced to duplicate operations in significantly higher-cost jurisdictions to appease Western supply chain security demands. This defensive CapEx deployment elevates fixed costs, increases depreciation expenses, and temporarily depresses overall asset turnover. While free cash flow generation is strong enough to absorb this burden without leveraging the balance sheet, the fragmentation of the manufacturing footprint prevents the company from achieving maximum theoretical operating leverage over the forecast horizon.	Not available%	-10.0%
Stagflationary Logistics Pressure	The Hormuz-driven global energy shock and the subsequent breakdown of the maritime insurance system impose severe inflationary pressures on global supply chains. As a highly globalized CRDMO, WuXi Biologics relies on the seamless international transit of temperature-sensitive biological materials, advanced laboratory equipment, and specialized reagents. The mechanism of this friction is the direct inflation of logistics, insurance, and raw material procurement costs. While the company boasts exceptional gross margins that can absorb significant shocks, the compounding effect of structurally higher freight rates and the requirement for elongated inventory buffering will erode incremental operating margins. This macro-level supply chain friction introduces persistent cost-of-goods-sold (COGS) headwinds that management must continuously outrun via pricing power.	Not available%	-10.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Formal Removal FROM 1260h Scrutiny	If the US Department of Defense explicitly issues guidance clearing WuXi Biologics of any military affiliation and officially exempts them from future 1260H listing, the geopolitical discount collapses completely. This trigger would mathematically force a massive multiple expansion as institutional capital, previously sidelined by compliance blockades, rushes back in to own a 20% compounder trading at distressed valuations.	35.0%	+60.0%
Massive Phase III Commercial Conversion	The pipeline currently holds 78 Phase III programs. If a disproportionately high percentage of these late-stage trials secure FDA/EMA approval and transition into full-scale commercial manufacturing, the revenue step-function will be violent. Commercial manufacturing carries massive operating leverage; capturing the lion's share of blockbuster ADC commercialization would trigger extreme upside surprises in free cash flow and net income.	45.0%	+30.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Formal DOD 1260h Designation	The ultimate bear catalyst: The US Department of Defense officially designates WuXi Biologics as a 'Biotechnology Company of Concern.' While existing contracts have a five-year safe harbor, the terminal value of the US business would immediately be priced at zero. Panic selling would ensue as passive index trackers and institutional funds are forced to mechanically divest the sanctioned equity.	25.0%	-60.0%
Chinese Retaliatory TECH Controls	If Beijing responds to the BIOSECURE Act or broader US tech blockades by instituting strict export controls on critical biologics intellectual property, cell lines, or raw materials, WuXi's 'Global Dual Sourcing' strategy breaks. The inability to seamlessly transfer technology from Chinese research hubs to Singapore/US manufacturing sites would paralyze operations and trigger massive breach-of-contract liabilities.	15.0%	-40.0%

Step-by-step forecast path

Sherlock Holmes forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_4c79d84a-a8e3-5211-bdfb-56a89b284731__sb5__20260605075858
Step	Forecast date	Step change	Projected value (HKD)	Scenario rationale
1	September 4, 2026	+18.0%	38.26	Q2 2026 earnings decisively crush the bear thesis, confirming the 69+ new projects (mostly US/EU) translate to robust revenue growth. The geopolitical discount begins to unwind sharply as the forensic evidence overrides the political panic.
2	December 4, 2026	+12.0%	42.85	The BIOSECURE Act's 5-year safe harbor and the omission of WuXi explicitly provides a green light for year-end US contract renewals. A relief rally sustains momentum as institutional compliance departments ease accumulation restrictions.
3	March 4, 2027	+10.0%	47.13	Full-year 2026 results reveal roughly 17% revenue growth and massive free cash flow generation. The 2 billion HKD buyback program accelerates, squeezing short sellers and driving structural multiple expansion.
4	June 4, 2027	-4.0%	45.25	The Warsh-led Fed's 'higher-for-longer' rate regime triggers a broader market rotation, temporarily capping multiple expansion as early-stage biotech funding constraints cause a slight deceleration in the pre-IND project funnel.
5	September 4, 2027	+8.0%	48.87	Operational updates confirm the successful ramp-up of the Singapore and US manufacturing hubs. This ex-China capacity materially de-risks the geopolitical narrative, validating the 'Global Dual Sourcing' strategy.
6	December 4, 2027	+15.0%	56.20	A wave of Phase III clinical projects successfully transitions into commercial manufacturing. The 'Follow and Win the Molecule' strategy proves its high-margin stickiness, driving a violent upside surprise in net income.
7	March 4, 2028	+8.0%	60.69	The 2027 annual report shows explosive growth in the ADC and bispecific segments. Gross margins remain structurally elevated above 46%, validating the intellectual property moat and absolute pricing power.
8	June 4, 2028	-5.0%	57.66	Global stagflationary headwinds, elevated energy costs, and a spike in the VIX create a generalized market pullback, dragging the stock down sympathetically despite perfectly clean idiosyncratic fundamentals.
9	September 4, 2028	+6.0%	61.12	The company leverages its pristine balance sheet to aggressively buy back shares during the mid-year macro dip. Management's relentless capital allocation discipline restores upward momentum.
10	December 4, 2028	+9.0%	66.62	Visibility into the 2029 multi-billion dollar backlog triggers deep institutional accumulation. The stock is increasingly viewed not as a geopolitical gamble, but as an unstoppable structural compounder.
11	March 4, 2029	+5.0%	69.95	Earnings beat expectations as operating leverage kicks in from fully utilized global facilities. Net margins push past historical ceilings, proving the duplicated CapEx was an optimal strategic necessity.
12	June 4, 2029	-3.0%	67.85	Minor profit-taking and sector rotation occur as investors digest the multi-year run. The fundamental thesis remains perfectly intact without material anomalies in the footnotes.
13	September 4, 2029	+7.0%	72.60	New breakthrough biologic approvals from WuXi's partners trigger massive milestone payments and commercial manufacturing volume surges, demonstrating the embedded call optionality in the client pipeline.
14	December 4, 2029	+6.0%	76.95	The impending expiration of the original 2025 BIOSECURE five-year safe harbor creates zero panic, as WuXi's global dual-sourcing network is fully operational and compliant, rendering the deadline irrelevant.
15	March 4, 2030	+8.0%	83.11	The 2029 financial closure proves the global capacity pivot was a masterstroke, capturing massive market share from legacy Western CDMOs that failed to match WuXi's execution speed in complex modalities.
16	June 4, 2030	-4.0%	79.79	Broad macroeconomic tightening and a reflexive de-risking in Asian equities temporarily drag down the stock, though the underlying business exhibits zero operational distress.
17	September 4, 2030	+5.0%	83.77	The unencumbered free cash flow machine insulates the company from macro volatility. The announcement of a special dividend or massive strategic acquisition reignites the aggressive bull case.
18	December 4, 2030	+7.0%	89.64	The company solidifies its position as the undisputed global leader in complex biologics manufacturing, operating a near-monopoly in certain high-value ADC pipelines.
19	March 4, 2031	+4.0%	93.22	Long-term institutional capital completes its accumulation phase. Earnings per share have more than doubled since 2026, mathematically forcing the final stage of structural multiple re-rating.
20	June 4, 2031	+6.0%	98.82	The five-year horizon concludes with WuXi Biologics achieving a Clean Bill of Health from a forensic perspective, having survived peak geopolitical stress to emerge as a dramatically stronger global entity.

Advisor and configuration

Advisor: sherlock_holmes__the_whistleblower__google_gemini_3_1_pro__20260201_preview_release
Persona: Sherlock Holmes
Archetype: The Whistleblower
Model: (February 01, 2026) Preview Release
Provider: Google
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: sherlock_holmes__the_whistleblower__google_gemini_3_1_pro__20260201_preview_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: sherlock_holmes__the_whistleblower__google_gemini_3_1_pro__20260201_preview_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Sherlock Holmes advisor methodology

Configuration components

aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643 (global_context)
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4 (task_guidelines)

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Elon Musk — THINKER with High Reasoning and Standard Creativity

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.